SCHEMBL2185393

SCHEMBL2185393

C=C(Cl)[C](F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87642 0.78
SCHEMBL28337137 0.74 ALDH1A1 (0.36)
Fluoride SCHEMBL20872434 0.74
Ethylene SCHEMBL4380013 0.74
1,1-Dichloroethene SCHEMBL10485690 0.74
1,1-Dichloroethene SCHEMBL3912308 0.74
SCHEMBL1248492 0.74
SCHEMBL1044411 0.73
SCHEMBL125620 0.72
Tetrafluoroethylene SCHEMBL1758390 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384512-A1 PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS Calico Life Sciences LLC (US) 2024-06-19 EP disclosed
EP-4359409-A1 DEGRADER COMPOUNDS AND USES THEREOF Calico Life Sciences LLC (US) 2024-05-01 EP disclosed
US-11951088-B2 Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome Epitracker, Inc. (US) 2024-04-09 US disclosed
US-20230355759-A1 POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 CELULARITY INC. (US) 2023-11-09 US disclosed
WO-2023137344-A1 CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF CELULARITY INC. (US) 2023-07-20 WO disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 CN disclosed
WO-2023019166-A1 PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS CALICO LIFE SCIENCES LLC (US) 2023-02-16 WO disclosed
WO-2023010123-A1 PLACENTA-DERVIED NK CELLS AS A SENOLYTIC FOR THERAPEUTIC AND OTHER USES CELULARITY INC. (US) 2023-02-02 WO disclosed
US-20230028680-A1 EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS CELULARITY INC. (US) 2023-01-26 US disclosed
WO-2023278628-A1 HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS IN ACUTE MYELOID LEUKEMIA (AML) REMISSION WITH MINIMAL RESIDUAL DISEASE (MRD) OR RELAPSED/REFRACTORY AML CELULARITY INC. (US) 2023-01-05 WO disclosed
WO-2016161160-A1 SPIROCYCLIC COMPOUNDS KALYRA PHARMACEUTICALS, INC. (US) 2016-10-06 WO disclosed
WO-2016138158-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2016-09-01 WO disclosed
US-20160244460-A1 ANTIVIRAL COMPOUNDS Janssen Pharmaceuticals, Inc. 2016-08-25 US disclosed
US-20150238498-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2015-08-27 US disclosed
EP-2888240-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS Alios Biopharma, Inc. (US) 2015-07-01 EP disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 US disclosed
WO-2014031784-A1 COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS ALIOS BIOPHARMA, INC. (US) 2014-02-27 WO disclosed
US-20120121861-A1 SURFACE PATTERNING WITH FUNCTIONAL POLYMERS BASF SE (DE) 2012-05-17 US disclosed
EP-2347303-A1 SURFACE PATTERNING WITH FUNCTIONAL POLYMERS BASF SE (DE) 2011-07-27 EP disclosed
WO-2010054979-A1 SURFACE PATTERNING WITH FUNCTIONAL POLYMERS BASF SE (DE) 2010-05-20 WO disclosed